REG - ConvaTec Group PLC - Total Voting Rights

ConvaTecAnnouncement

01/11/2021 15:35

RNS Number : 9601Q
  
ConvaTec Group PLC
  
01 November 2021
  
 

ConvaTec Group Plc ("the Company") - Total Voting Rights
Reading, United Kingdom (1 November 2021)
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 October 2021, the Company's issued capital with voting rights consisted of 2,014,572,935 ordinary shares of 10p each ('Shares'). The Company does not hold any Shares in Treasury at the date of this disclosure.
The above figure (2,014,572,935) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the UK Financial Conduct Authority's Disclosure and Transparency Rules.  
 
Enquiries:
Analysts and Investors 
Kate Postans, Vice President, Investor Relations                                                +44 (0)7826 447 807
ir@convatec.com
 
Media 
Buchanan: Charles Ryland/Chris Lane/ Hannah Ratcliff                                      +44 (0)207 466 5000  
 
 
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
 
About ConvaTec 
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
TVRZZMGMKMFGMZM